11
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      What made sesquiterpene lactones reach cancer clinical trials?

      , , , ,
      Drug Discovery Today
      Elsevier BV

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Sesquiterpene lactones (SLs) are plant-derived compounds often used in traditional medicine against inflammation and cancer. This review focuses on the chemical and biological properties of SLs that lead to enhanced anticancer and anti-inflammatory effects. The chemical properties comprise alkylating center reactivity, lipophilicity, and molecular geometry and electronic features. SLs in clinical trials are artemisinin, thapsigargin and parthenolide and many of their synthetic derivatives. These drugs are selective toward tumor and cancer stem cells by targeting specific signaling pathways, which make them lead compounds in cancer clinical trials.

          Related collections

          Author and article information

          Journal
          Drug Discovery Today
          Drug Discovery Today
          Elsevier BV
          13596446
          August 2010
          August 2010
          : 15
          : 15-16
          : 668-678
          Article
          10.1016/j.drudis.2010.06.002
          20541036
          797817dd-4e27-40a4-95dc-d27639b6d186
          © 2010

          https://www.elsevier.com/tdm/userlicense/1.0/

          History

          Comments

          Comment on this article